NasdaqNASDAQ: NDAQ

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode's request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D).

On November 4, 2024, Olema Pharmaceuticals, Inc. announced that it has granted stock options to a new employee, allowing them to buy a total of 2,500 shares of the company's common stock, starting from November 1, 2024. This decision was made by the Compensation Committee of Olema's Board of Directors and is part of the 2022 Inducement Plan. The grant is intended to encourage new employees to join Olema, following Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company focused on developing innovative cellular immunotherapies from induced pluripotent stem cells (iPSCs) for cancer and autoimmune diseases, announced that on November 1, 2024, it granted 20,000 restricted stock units (RSUs) to a new non-executive employee. This grant was approved by the Compensation Committee of the Board of Directors and is part of the Company's Amended and Restated Inducement Equity Plan, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting each year on the anniversary of the grant, provided the employee remains with the Company.

WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company specializing in immuno-dermatology, has announced the granting of 50,000 restricted stock units and options to buy 50,000 shares of its common stock to five new employees. These awards were approved by the Compensation Committee of the Board of Directors and are part of the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, effective from November 1, 2024, to encourage the new hires to join the company, in line with Nasdaq Listing Rule 5635(c)(4).

As the U.S. election approaches and the Federal Reserve is expected to lower interest rates, the mood in the stock market is uncertain. Important choices made during this time could influence trading patterns as the year comes to a close.

The US Indices are currently stable as we await the outcome of election night and the Federal Reserve's decision on Thursday. Right now, the markets seem to be just passing the time.

SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) is a top marketing technology firm that offers important marketing and sales solutions. The company has been given the green light by the Nasdaq Stock Market's Listing Qualifications Department to move its listing to the Nasdaq Capital Market. As of October 31, 2024, the company's securities have officially shifted from the Nasdaq Global Market to the Nasdaq Capital Market.

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a biopharmaceutical company focused on developing innovative small molecule treatments for cancer, announced that on November 1, 2024, its Compensation Committee granted stock options for 79,500 shares and 21,000 restricted stock units to three new employees. These grants were made under the 2022 Employment Inducement Incentive Award Plan to encourage the new hires to join the company, in line with Nasdaq Listing Rule 5635(c)(4).

DevvStream is making progress on its merger with Focus Impact Acquisition Corp. and plans to list on the Nasdaq. The company, which focuses on technology-driven carbon credit projects, provided an update on this merger, which was first announced on September 13, 2023. If successful, this merger will make DevvStream the first publicly traded carbon streaming company on a major U.S. stock exchange.